LHRH analogues as primary treatment for urinary retention in patients with prostatic carcinoma

Br J Urol. 1993 May;71(5):583-6. doi: 10.1111/j.1464-410x.1993.tb16029.x.

Abstract

Thirty-one patients with retention of urine and carcinoma of the prostate were treated with LHRH analogues as primary therapy rather than prostatectomy; 21 patients voided without the need for surgical intervention. Patients presenting in acute retention of urine voided more readily than those presenting in chronic retention, with only 20% requiring surgery. This approach to treatment is safe, efficacious and cost effective.

MeSH terms

  • Acute Disease
  • Aged
  • Chronic Disease
  • Goserelin / therapeutic use*
  • Humans
  • Male
  • Prostate / pathology
  • Prostatic Neoplasms / complications
  • Prostatic Neoplasms / drug therapy*
  • Prostatic Neoplasms / pathology
  • Urinary Retention / drug therapy*
  • Urinary Retention / etiology
  • Urination

Substances

  • Goserelin